Merck execs' bailout loot

Cowboy hat By Jim Hightower - Sat., 1/1/05

When drugmaker Merck recently withdrew its best-selling drug Vioxx (because it can cause heart attacks) company executives took their time disclosing this little problem to regulators, doctors, or patients, and now the company faces federal investigations and thousands of lawsuits.

Merck's stock price has plummeted by 40 percent, on top of a 30 percent slide caused by a lack of new products, all of which makes it a likely target for a takeover by another drug giant.

But Merck executives are quick on their feet when protecting their own personal interests. Their exec retirement plan says that if another company takes over Merck—or even just 20 percent of it—the top 230 executives can bail out with a golden parachute of three times their annual salaries, plus their expected bonuses, as well as stock payments. For example, CEO Raymond Gilmartin, who helped engineer this sweet deal, would get about $57 million to soften his landing.